MaxCyte (NASDAQ:MXCT) & Polarean Imaging (OTCMKTS:PLLWF) Head to Head Analysis

MaxCyte (NASDAQ:MXCT) and Polarean Imaging (OTCMKTS:PLLWF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Profitability

This table compares MaxCyte and Polarean Imaging’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MaxCyte	-77.97%	-15.52%	-13.57%
Polarean Imaging	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for MaxCyte and Polarean Imaging, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	0	0	4	0	3.00
Polarean Imaging	0	0	0	0	N/A

MaxCyte presently has a consensus price target of $8.67, suggesting a potential upside of 128.07%. Given MaxCyte’s higher probable upside, analysts clearly believe MaxCyte is more favorable than Polarean Imaging.

Insider and Institutional Ownership

68.8% of MaxCyte shares are held by institutional investors. 3.0% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares MaxCyte and Polarean Imaging”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$45.44 million	8.77	-$37.92 million	($0.35)	-10.86
Polarean Imaging	N/A	N/A	N/A	N/A	N/A

Polarean Imaging has lower revenue, but higher earnings than MaxCyte.

Summary

MaxCyte beats Polarean Imaging on 5 of the 8 factors compared between the two stocks.

About MaxCyte

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

About Polarean Imaging

Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas polarizer devices in Canada, the United Kingdom, and the United States. The company engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. It also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; and measurement station, chest coil, and dose delivery inhalation bags. Polarean Imaging plc was incorporated in 2016 and is based in Durham, North Carolina.